Enclomiphene at a glance
A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.
Enclomiphene is the trans-isomer of clomiphene citrate and acts as a selective estrogen receptor antagonist (SERM) at the hypothalamus and pituitary. By blocking estrogen's negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis, it increases pulsatile GnRH secretion, which in turn elevates LH and FSH output from the pituitary, thereby stimulating Leydig cell testosterone synthesis.
Unlike exogenous testosterone replacement therapy (TRT), enclomiphene raises endogenous testosterone levels without suppressing spermatogenesis - making it attractive for hypogonadal men who wish to maintain or restore fertility. Phase 2 and Phase 3 clinical trials demonstrated that enclomiphene citrate (12.5 - 25 mg/day orally) raised morning testosterone into the eugonadal range in secondary hypogonadism patients while maintaining sperm counts comparable to baseline.
The cis-isomer of clomiphene (zuclomiphene) has partial estrogenic agonist activity and a much longer half-life, contributing to side effects associated with standard clomiphene. Enclomiphene, by isolating only the trans-isomer, offers a cleaner pharmacological profile with fewer estrogenic side effects such as mood disturbances and visual symptoms.
An NDA was submitted to the FDA for enclomiphene (Androxal) for secondary hypogonadism treatment; while full approval was not granted due to trial design concerns, the compound remains widely used off-label in men's health clinics as an alternative or adjunct to TRT.
Key Benefits
Saves this peptide to your Watchlist and helps you find new research, news, and questions later.